Use of Funds
$15M funding to launch three tests and begin to revenue
To date: IP development of StromaGenesis funded using ~$10MM in Grants
[NIH/DOD/State Funds]
CEO Richard Pestell, MD acquired the Algorithm [asset] from CytoDyn 6/22.
[BDO Valuation $9.6MM]
CEO Richard Pestell, MD acquired additional assets on 6/22 [~$1.5MM expended]
These funds have provided verification of the algorithm and Clinical Trial materials supported by 36 publications.
100 East Lancaster Ave
Room R234
Wynnewood, Pennsylvania 19096
General inquiries:
© 2025 StromaGenesis. All rights reserved.
Privacy Policy